Colombia is one of Latin America’s most active clinical trial destinations, and every interventional study involving a medicinal product in human subjects has to clear a single national gatekeeper: INVIMA, the Instituto Nacional de Vigilancia de Medicamentos y Alimentos. For sponsors, CROs, and research administrators used to FDA IND or EMA CTA processes, INVIMA’s pathway follows a recognizably similar logic — ethics review, a national regulatory “no objection,” and ongoing Good Clinical Practice (GCP) oversight — but it runs on Colombia-specific instruments that don’t map one-to-one onto those systems. This guide covers the confirmed current framework and, separately, what has and has not actually changed heading into and through 2026.
What INVIMA is and what it regulates
INVIMA is Colombia’s national health-products regulatory authority, attached to the Ministry of Health and Social Protection. Beyond its better-known role authorizing drugs, biologics, and medical devices for the Colombian market, INVIMA is the competent authority for clinical trials conducted in the country — no clinical research project involving medicinal products in human subjects may begin without INVIMA’s approval or prior “visto bueno” (no-objection), regardless of the sponsor’s country of origin.
INVIMA’s clinical trial function sits within its medicines and biologics oversight structure, which publishes trial-specific guidance and forms through its own site (invima.gov.co — Ensayos Clínicos). Institutions and sponsors working in Colombia should treat that page, not third-party summaries, as the authoritative source for current forms, checklists, and submission guides — INVIMA revises its guías (guides) and formatos (forms) on a rolling basis independent of any broader legislative change.
The regulatory backbone: Resolution 2378 of 2008 and Resolution 8430 of 1993
Two instruments do most of the structural work:
- Resolución 2378 de 2008 (Ministry of Social Protection) formally adopted Good Clinical Practice as mandatory for institutions conducting drug research in human subjects in Colombia. It requires institutions to hold INVIMA-issued GCP certification (valid five years), establishes that no drug research project may start without INVIMA approval or prior no-objection, and requires each investigating institution to maintain an institutional ethics committee meeting the requirements set out in the resolution’s technical annex. INVIMA retains authority to interrupt a study for non-compliance or public-health risk.
- Resolución 8430 de 1993 (Ministry of Health) is Colombia’s foundational human-subjects-research regulation, predating Resolution 2378 by fifteen years. It classifies research by risk level — investigación sin riesgo (no risk), con riesgo mínimo (minimal risk), and con riesgo mayor al mínimo (greater than minimal risk) — a classification that still shapes what level of ethics review and INVIMA scrutiny a given study receives.
Together these two resolutions function as Colombia’s equivalent of an FDA-style human-subjects/GCP regulatory core, though they are older and narrower in scope than ICH E6 — INVIMA guidance separately expects alignment with ICH-GCP for sponsors seeking data that will support international regulatory submissions.
The approval pathway, step by step
- Institutional readiness. The investigating institution must hold current INVIMA GCP certification and have a qualified institutional ethics committee (comité de ética institucional) constituted per the Resolution 2378 technical annex.
- Ethics committee review. The protocol, informed consent documents, investigator’s brochure, and supporting materials go to the institutional ethics committee before or in parallel with the INVIMA submission, consistent with the risk classification under Resolution 8430.
- Protocol dossier to INVIMA. The sponsor or institution files the clinical trial protocol — study design, objectives, methodology, statistical analysis plan — together with the informed consent document, investigator’s brochure, and required administrative forms through INVIMA’s submission channel.
- INVIMA technical review and no-objection. INVIMA’s clinical trials group reviews the dossier for scientific, ethical, and safety adequacy. A study may not begin enrollment until INVIMA has issued its approval or “visto bueno” (no-objection).
- Ongoing compliance and inspection. Once underway, the trial is subject to INVIMA’s Good Clinical Practice enforcement (fiscalización), including the authority to inspect sites and suspend a study for non-compliance or safety concerns.
CASRAI is not able to confirm a specific, current statutory review-timeline figure or fee schedule for this pathway from primary INVIMA sources as of this writing; both are subject to INVIMA’s periodically-updated tariff resolutions (INVIMA publishes an annual Manual Tarifario) and case-specific factors (product type, risk classification, completeness of the initial dossier). Sponsors should confirm current timelines and fees directly against INVIMA’s published Manual Tarifario and clinical-trials guidance rather than relying on a fixed figure from secondary sources, which vary and go stale quickly.
The institutional ethics committee’s role
Resolution 2378 requires every institution conducting drug research on human subjects to maintain its own institutional ethics committee, reviewed against the resolution’s technical annex — distinct from, though functionally analogous to, an IRB in the U.S. system or a Research Ethics Committee (REC) in the UK/EU. For “above minimal risk” research specifically, ethics committee review is a substantive gate, not a formality — committees assess informed consent adequacy, risk-benefit balance, and participant protections independently of INVIMA’s own technical review. Sponsors working across multiple Colombian sites should expect to coordinate with each site’s institutional committee individually unless a central/shared review arrangement has been agreed, since Colombia’s framework is built around institution-level committees rather than a single national IRB.
What has genuinely changed for 2026 — and what has not
The premise that INVIMA underwent a single, comprehensively-branded “2026 regulatory framework overhaul” for clinical trials specifically is not something CASRAI could confirm against INVIMA’s own published normativa or independent regulatory-affairs reporting. What is confirmed, and is worth tracking separately, is a set of real but narrower 2026 developments:
- New Virtual Office submission platform (effective June 2, 2026). INVIMA’s Oficina Virtual moved from a “free dossier” model — documents organized loosely into a small number of files — to structured, field-by-field document upload, with payment integrated into the filing flow and automatic assignment of the radicado (filing number) after payment. This is a procedural/platform change that applies broadly across INVIMA’s sanitary filings (registrations, renewals, modifications, requirement responses), not a clinical-trial-specific reform, but it does affect how trial-related submissions to INVIMA are physically filed going forward. Notably, the prior no-cost preliminary correction stage (Citizen Care Office filter) was eliminated, and payments can no longer be reused if a filing is returned for deficiencies — sponsors and regulatory-affairs teams should build additional dossier-completeness review into their internal process before submission under the new system.
- A long-pending update to Colombia’s core pharmaceutical decree (Decreto 677 de 1995). As of early 2026, Colombia’s ~30-year-old foundational pharmaceutical regulation was reported to be under active reform discussion, with stated aims including faster INVIMA registration timelines, closer alignment with FDA/EMA data-recognition practices, and stronger post-market surveillance. As of this writing this reform had not been confirmed as finalized, and available reporting on it addresses medicines registration and post-market oversight rather than the clinical-trial-approval pathway specifically — it is adjacent context, not a confirmed clinical-trials rule change.
- Sector-specific regulatory activity elsewhere at INVIMA (for example, a 2026 deadline for INVIMA to issue new medicinal-cannabis regulations under Decreto 1138 de 2025, and revised guidance on post-registration sanitary-registry modifications) reflects a generally active regulatory year at the agency, but these items are also not clinical-trial-approval-specific.
Net assessment for sponsors and research administrators planning Colombian trial activity in 2026: budget time to adapt to the new Virtual Office filing mechanics, and monitor INVIMA’s own Normatividad Interna page for the Decreto 677 reform’s actual status, but do not plan around an assumed comprehensive clinical-trials-specific regulatory overhaul that current primary sources do not confirm exists. This page will be revisited if and when a confirmed, trial-specific reform is formally adopted.
How INVIMA’s pathway compares to ICH-GCP-aligned systems
INVIMA guidance and Colombian regulatory-affairs practice both expect trial conduct to meet ICH GCP standards, particularly for trials intended to support submissions to ICH-member regulators (FDA, EMA, and others). This means a Colombia-approved protocol built on ICH E6(R2) principles, with informed consent and safety-reporting practices consistent with the ICH E-series, will generally translate cleanly into a Colombian ethics-committee and INVIMA submission — but the Colombian approval mechanism itself (institutional GCP certification, institution-level ethics committees, INVIMA no-objection) is a distinct national instrument, not a harmonized regional one. Sponsors running multi-country Latin American trials should expect Colombia’s pathway to sit alongside, not substitute for, country-specific requirements in jurisdictions such as Brazil (ANVISA/CONEP) or Mexico (COFEPRIS) — CASRAI does not yet have dedicated guides to those pathways, but the institutional logic (national regulator plus local/institutional ethics review) is broadly similar across the region.
Frequently asked questions
Does INVIMA approve every clinical trial in Colombia, or only drug trials?
INVIMA’s clinical-trials approval authority under Resolution 2378 of 2008 covers research involving medicinal products (drugs and biologics) in human subjects. Medical-device studies and other categories of human-subjects research fall under related but distinct INVIMA and Ministry of Health frameworks — sponsors should confirm which regulatory track applies based on the product category before assuming the drug-trial pathway described here applies directly.
Can a foreign sponsor submit directly to INVIMA, or is a local institution required?
Resolution 2378’s institutional requirements (GCP certification, an institutional ethics committee) are structured around the Colombian investigating institution, which is why foreign sponsors conducting trials in Colombia typically work through a local site, institution, or CRO with current INVIMA GCP certification rather than filing directly as an unaffiliated foreign entity.
How long does INVIMA’s clinical trial review typically take?
CASRAI has not been able to confirm a fixed statutory timeline from INVIMA’s own primary sources; secondary sources cite varying figures that are not reliable enough to publish as fact. Sponsors should request current expected timelines directly from INVIMA or a Colombia-based regulatory-affairs partner as part of pre-submission planning.
Is the 2026 Virtual Office change relevant if my trial is already approved and underway?
It primarily affects new filings and post-approval submissions (modifications, renewals, requirement responses) made through INVIMA’s Oficina Virtual from June 2, 2026 onward — ongoing trials should expect any further INVIMA filings after that date to follow the new structured-upload, integrated-payment process rather than the prior free-dossier format.
Related CASRAI resources
For the broader Good Clinical Practice framework INVIMA expects trials to align with, see ICH GCP (Good Clinical Practice) and Good Clinical Practice (GCP) Certification. For informed consent requirements that Colombian ethics committees assess, see The Informed Consent Process in Clinical Trials and ICF (Informed Consent Form). For protocol structure expectations that carry into an INVIMA submission dossier, see Designing a Clinical Trial Protocol. For funding-side context on doing research in Colombia and neighboring countries, see ANID Chile (Fondecyt), SECIHTI Mexico, and CNPq Brazil. For the wider clinical research administration knowledge base, see the Clinical Research Administration pillar.
